Efficacy and safety analysis of Dupilumab for atopic dermatitis of all ages in Chinese population: Real-world data from a single center

Allergy. 2024 May;79(5):1379-1382. doi: 10.1111/all.16078. Epub 2024 Feb 29.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Asian People
  • Child
  • Child, Preschool
  • China / epidemiology
  • Dermatitis, Atopic* / drug therapy
  • East Asian People
  • Female
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Treatment Outcome
  • Young Adult

Substances

  • dupilumab
  • Antibodies, Monoclonal, Humanized